AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30693096
Drug: Usual IAPT
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual IAPT treatment alone
Trial: 29927785
Drug: Intravenous zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid (ZOL) 5 mg annually for 2 years
Trial: 29927785
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from tenofovir disoproxil fumarate (TDF) to another active antiretroviral drug
Trial: 27239927
Drug: Clopidogrel 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 150 mg + ASA 300 mg (Subgroup 2)
Trial: 27239927
Drug: ASA 300
RxNorm normalized name: ASA 300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 300 mg + Ticagrelor 90 mg twice daily (Subgroup 3)
Trial: 27239927
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg + ASA 300 mg (Subgroup 1)
Trial: 25336097
Drug: Nasal saline
RxNorm normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal saline irrigation (isotonic and hypertonic solutions)
Trial: 25336097
Drug: Nasal aspiration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal aspiration with isotonic saline solution
Trial: 25336097
Drug: Isotonic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic and hypertonic saline solutions
Trial: 20214777
Drug: Web-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based self-help intervention based on Cognitive Behavioural Therapy (CBT)
Trial: 8617554
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg daily for 5 days
Trial: 8617554
Drug: Metronidazole 7.5
RxNorm normalized name: metronidazole 7.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 7.5 mg/Kg thrice daily for 5 days
Trial: 8617554
Drug: Metronidazole therapy
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole therapy
Trial: 2765377
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg or 20 mg)
Trial: 26635296
Drug: Consensus messages
RxNorm normalized name: Consensi
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consensus messages about vaccine safety (90% of medical scientists agree vaccines are safe)
Trial: 18316547
Drug: Panitumumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab (6 mg/kg every other week)
Trial: 10724054
Drug: Subset of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subset of 1034 patients with CAUTI (89 with >103 colony-forming units/mL)
Trial: 8754444
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (group A)
Trial: 8754444
Drug: No thrombolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No thrombolytic therapy (group B)
Trial: 8754444
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy in patients with left ventricular dysfunction
Trial: 8754444
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy in patients with symptom delay > 4 hours
Trial: 24467369
Drug: Aripiprazole (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (0, 2 or 10 mg/day/p.o.)
Trial: 22236488
Drug: Disease management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease management approach including systematic screening, treatment upon positive screening, monitoring, and intensified treatment in case of non-remission.
Trial: 18346028
Drug: Artesunate plus
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate plus amodiaquine (ASAQ) - artesunate 4 mg/kg daily and amodiaquine 10 mg/kg daily for 3 days.
Trial: 18346028
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (AL) - 5-14 kg: one tablet; 15-24 kg: two tablets; 25-34 kg: three tablets, twice daily for 3 days.
Trial: 16259789
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 600 mg reduced glutathione per day
Trial: 16259789
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 50 mg alpha‐lipoic acid per day
Trial: 16259789
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 100 mg N‐acetylcysteine per day
Trial: 16259789
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ST) based on WHO recommendations
Trial: 12207629
Drug: Nebulizer with
RxNorm normalized name: AeroNeb Go Nebulizer with Cable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer with 25 g oral charcoal (NEBC)
Trial: 12207629
Drug: Metered Dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered Dose Inhaler (MDI) vs Oral (ORAL)
Trial: 12207629
Drug: Nebulizer (NEB)
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer (NEB) vs Oral (ORAL)
Trial: 7476326
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg/d for 12 months
Trial: 23890351
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg monacolins
Trial: 21291335
Drug: Miglitol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (50 mg) before meals
Trial: 21291335
Drug: Acarbose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (100 mg) before meals
Trial: 9404766
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg nebulized 2% lidocaine
Trial: 9404766
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg nebulized 2% lidocaine
Trial: 3066965
Drug: Hypothiazide 25
RxNorm normalized name: CYCLOTHIAZIDE
DrugBank: Cyclothiazide (DB00606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypothiazide 25 mg
Trial: 3066965
Drug: Hypothiazide 50
RxNorm normalized name: CYCLOTHIAZIDE
DrugBank: Cyclothiazide (DB00606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypothiazide 50 mg
Trial: 3066965
Drug: Hypothiazide 100
RxNorm normalized name: CYCLOTHIAZIDE
DrugBank: Cyclothiazide (DB00606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypothiazide 100 mg
Trial: 3066965
Drug: Oxodoline 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxodoline 50 mg
Trial: 3066965
Drug: Oxodoline 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxodoline 100 mg
Trial: 25618800
Drug: Curcuminoid-piperine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoid-piperine combination (1 g curcuminoids + 10 mg piperine daily)
Trial: 25618800
Drug: Curcuminoid-piperine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoid-piperine combination
Trial: 20513160
Drug: LCD 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCD 15% solution (Psorent)
Trial: 20513160
Drug: Calcipotriene 0.005%
RxNorm normalized name: CALCIPOTRIENE 0.005% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene 0.005% cream (Dovonex)
Trial: 18226128
Drug: Extra-amniotic saline
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic saline solution infusion (EASI) plus dexamethasone 20 mg
Trial: 18226128
Drug: Extra-amniotic saline
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic saline solution infusion (EASI) alone
Trial: 16967629
Drug: E2/norgestimate (NGM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/norgestimate (NGM) 1 mg/90 microg
Trial: 9011450
Drug: Orlistat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (200 mg)
Trial: 1334255
Drug: Live oral
RxNorm normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live oral tetravalent human‐rhesus rotavirus reassortant vaccine
Trial: 29321218
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline administration
Trial: 25298578
Drug: Lafutidine 10
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafutidine 10 mg once daily for 8 weeks
Trial: 25298578
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg once daily for 8 weeks
Trial: 15127186
Drug: 4% modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% modified fluid gelatine (GEL)
Trial: 11899903
Drug: SRL172 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRL172 with chemotherapy (n=14)
Trial: 11899903
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (n=14)
Trial: 11899903
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment regimens (SRL172 + chemotherapy and chemotherapy alone)
Trial: 11899903
Drug: SRL172 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRL172 with chemotherapy
Trial: 2678635
Drug: Verapamil (VP)
RxNorm normalized name: VP-14637
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil (VP) therapy prior to administration of CsA
Trial: 2678635
Drug: Verapamil (VP)
RxNorm normalized name: VP-14637
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil (VP) therapy
Trial: 31479196
Drug: Myjet-assisted transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myjet-assisted transdermal injection of tranexamic acid (TA)
Trial: 31479196
Drug: Myjet-assisted transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myjet-assisted transdermal injection of vitamin C (VC)
Trial: 26301771
Drug: brexpiprazole 3
RxNorm normalized name: brexpiprazole 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole 3 mg
Trial: 23735680
Drug: DEN1Δ30 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEN1Δ30 at 10PFU and 1000PFU doses
Trial: 23735680
Drug: DEN2/4Δ30 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEN2/4Δ30 at 10PFU and 1000PFU doses
Trial: 23735680
Drug: DEN3Δ30/31 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEN3Δ30/31 at 10PFU and 1000PFU doses
Trial: 23735680
Drug: DEN1Δ30 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEN1Δ30 at 1000PFU and 10PFU doses
Trial: 21183518
Drug: Intracameral lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracameral lidocaine 1% (0.5 cc)
Trial: 19877967
Drug: Benznidazole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benznidazole (5 mg/kg per day for 30 days)
Trial: 12956652
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine spray applied twice daily
Trial: 12956652
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine spray applied once daily plus placebo spray once daily
Trial: 1559584
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg (150 mg if B.W. < 40 kg) as a single evening dose for four weeks
Trial: 25151658
Drug: Mometasone nasal
RxNorm normalized name: mometasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone nasal spray for six months
Trial: 25151658
Drug: Saline nasal
RxNorm normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline nasal spray for six months
Trial: 19851798
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) isomers (3.9 g per day, 50:50 t9c11:c10t12)
Trial: 19851798
Drug: Placebo (high-oleic-acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (high-oleic-acid sunflower oil, 3.9 g per day)
Trial: 12384357
Drug: Ertapenem (INVANZ)
RxNorm normalized name: ertapenem Injection [Invanz]
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertapenem (INVANZ) at doses up to 3 g
Trial: 10103305
Drug: GM‐CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF (10 microg/kg/d) by subcutaneous injection for 5 days
Trial: 10103305
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GM‐CSF treatment)
Trial: 7577779
Drug: Fentanyl added
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl added to mepivacaine (75 micrograms with 30 mL mepivacaine 1.5% with epinephrine 5 micrograms/mL)
Trial: 23301674
Drug: Comprehensive eye
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive eye assessment including visual acuity, orthoptic assessment, cycloplegic autorefraction, ocular biometric variables, and ophthalmic photographs.
Trial: 20860867
Drug: Enriched Supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched Supportive Therapy (Control)
Trial: 10679908
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) alpha and beta (>10 U/mL), long-term exposure (144 hr)
Trial: 2863380
Drug: Neuroleptic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic group (maintenance antipsychotic medication)
Trial: 2863380
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drug-free)
Trial: 27259552
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily antibiotic prophylaxis for 12 months
Trial: 24261328
Drug: Citrate-enriched bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate-enriched bicarbonate based dialysate (CD) with 30% reduced heparin dose
Trial: 24261328
Drug: Acetate-enriched bicarbonate
RxNorm normalized name: potassium acetate / potassium bicarbonate / potassium citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate-enriched bicarbonate based dialysate with standard heparin dose of ∼ 100 IU/kg (Treatment A)
Trial: 22889151
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) with chemotherapy for 6 months, followed by 3 months follow-up
Trial: 22889151
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without UDCA for 9 months
Trial: 18826853
Drug: Standard phosphate-binder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard phosphate-binder therapy (Stx)
Trial: 15796145
Drug: Protenplus (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protenplus (oral protein-energy supplement)
Trial: 10542989
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with heat killed Mycobacterium vaccae
Trial: 28687232
Drug: Mepolizumab (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (750 mg IV every 4 weeks for 6 doses)
Trial: 19244174
Drug: Goserelin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.6 mg injection every 4 weeks for 2 years)
Trial: 19244174
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 or 40 mg daily for 2 years)
Trial: 16320180
Drug: Control group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, received no treatment
Trial: 9676352
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline (500 mg) with standard breakfast
Trial: 9676352
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline (500 mg) with cholecystokinin (0.3 microgram/kg)
Trial: 9676352
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline (500 mg) under fasting conditions
Trial: 3054451
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX, 1,000 mg/m2)
Trial: 3054451
Drug: Cranial irradiation/sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial irradiation/sequential chemotherapy (RTSC)
Trial: 23894039
Drug: 1 year
RxNorm normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 year trastuzumab treatment
Trial: 16825698
Drug: Six-month plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-month plasma ferritin concentrations <12 microg/L in HIV-negative infants
Trial: 9744143
Drug: Nisoldipine coat-core
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine coat-core (CC) 20-40 mg once daily
Trial: 30825342
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (CT) intervention (resistance plus endurance training) for 20 weeks
Trial: 27955850
Drug: YES IN
RxNorm normalized name: Cha Ye
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YES IN (Oral immunonutrition) administered for 8 days (3 sachets a day)
Trial: 27955850
Drug: NOT IN
RxNorm normalized name: Blood group antigen associated with but not included in MNS system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOT IN (no immunonutrition) in patients with rectal cancer
Trial: 27955850
Drug: YES IN
RxNorm normalized name: Cha Ye
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YES IN (Oral immunonutrition)
Trial: 24148035
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (no housing or support)
Trial: 20924595
Drug: Quercetin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 150 mg
Trial: 19781408
Drug: Anacetrapib, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib, 100 mg
Trial: 28916311
Drug: Lenalidomide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (5 mg daily, escalated to 15 mg if tolerated)
Trial: 12859326
Drug: Protease inhibitors
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitors (PIs) in the salvage regimen
Trial: 12859326
Drug: >8 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >8 months on treatment
Trial: 12859326
Drug: Virological responders
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Virological responders (> or =1 log10 HIV-1 RNA copies/mL decrease)
Trial: 11339007
Drug: Lugol's iodine
DrugBank: Potassium triiodide (DB14492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lugol's iodine treatment
Trial: 8970407
Drug: Metoprolol OROS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol OROS 190 mg once daily
Trial: 8970407
Drug: Metoprolol OROS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol OROS 285 mg once daily
Trial: 8970407
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg 2 or 3 times daily
Trial: 6373331
Drug: Topical 0.125%
RxNorm normalized name: sodium hypochlorite topical 0.125% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.125% clonidine
Trial: 31537473
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (30-40 sessions, 100% oxygen, breathed at a pressure of 240-250 kPa, for 80-90 min daily)
Trial: 30052208
Drug: Dexmedetomidine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.8 μg/kg/h)
Trial: 30052208
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 mg/kg/h)
Trial: 23672209
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection with needle electromyographic guidance (Group A, 15 patients)
Trial: 23672209
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection without electromyographic guidance (Group B, 12 patients)
Trial: 17666915
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg/day and Valsartan 80 mg/day (combination)
Trial: 15020512
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg/day for three weeks)